BioVersys AG Alternatives & Competitors

12 companies similar to BioVersys AG — Leadership in overcoming the antibiotic resistance crisis.

Adaptive Phage Therapeutics

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cu...

28 Acquired $112.11M

Gaithersburg, United Stat...

Biotechnology Health Care +2

Compare

Apidel

Revolutionizing Therapeutics through Cutting-Edge Drug Delivery Solutions

Series C

Biotechnology Pharmaceutical

Compare

EOLO PHARMA

Cutting-Edge Pharmacological Treatment for Obesity

12 Venture round $4.50M

San Francisco, United Sta...

Biopharma Biotechnology +2

Petra Pharma

Pioneering novel therapies to address cancer and metabolic disorders by targeting essentia...

Debt Financing $75.55M

Biotechnology Health Care +2

Track all BioVersys AG competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Pharmasset, Inc.

11 Post-IPO Equity $115.70M

Biotechnology Health Care +1

Maxwell Biosciences

Next Generation Anti-Infectives: A drug platform confirmed by independent labs to destroy...

22 $33.80M

Austin, United States

Biotechnology Pharmaceutical

Promontory Therapeutics

Phase 2 stage biotech company developing novel small-molecule anti-cancer immunotherapies.

15 Series A $72.01M

New York, United States

Biotechnology Life Sciences +1

Microbion Corporation

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic,...

16 Venture round

Bozeman, United States

Biotechnology Health Care +2

Spero Therapeutics

Clinical-stage biotech company focused on rare diseases and diseases with high unmet need

44 IPO $374.60M

Cambridge, United States

Biotechnology Pharmaceutical

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals (ASX:RCE) is pioneering a New Class of Synthetic Anti-Infectives to...

19 Grant $39.00M

Australia

Biotechnology Pharmaceutical

Allecra Therapeutics

Our Mission: Answering the call to action to fight antibiotic resistance

7 Series B $37.00M

Biopharma Biotechnology +1

N-Gene Research Laboratories, Inc.

3 Private Equity $3.00M

Biotechnology Pharmaceutical

About BioVersys AG

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company founded in 2008. It focuses on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. The company's award-winning TRIC technology h...

Business keywords

Pharmaceuticals, Antimicrobial Resistance, Drug Development, Microbiome Modulation, Small Molecules, Clinical Stage, Swiss Company, Research And Development, Nosocomial Infections, Acinetobacter Baumannii, Tuberculosis, Collaboration With GlaxoSmithKline, University Consortium, TechPark Basel

Frequently Asked Questions

Companies similar to BioVersys AG include Adaptive Phage Therapeutics, Apidel, EOLO PHARMA, Petra Pharma, Pharmasset, Inc.. They work in Biotechnology and Pharmaceutical and share BioVersys AG's focus on drug development, pharmaceuticals and research and development.

Bounce Watch lists 12 companies that share BioVersys AG's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches BioVersys AG and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

BioVersys AG Profile Apidel Alternatives EOLO PHARMA Alternatives Petra Pharma Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at BioVersys AG on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.